Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial
Official title:
Expanded Access Program for Magrolimab
The goal of this expanded access program is to provide rapid access to magrolimab free-of-cost material, to treat patients in the United States suffering from relapsed or refractory acute myeloid leukemia (AML).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05731219 -
UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05061147 -
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05548088 -
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Terminated |
NCT03504410 -
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
|
Phase 3 | |
| Withdrawn |
NCT03904069 -
Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML
|
Phase 1 | |
| Completed |
NCT05518357 -
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT03190278 -
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT02665143 -
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
|
Phase 2 | |
| Completed |
NCT03886831 -
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT05722171 -
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Early Phase 1 | |
| Completed |
NCT03318016 -
Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT06084819 -
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 2 |